Created On: 2020-07-15
Record Count: 4
- Alzheimerâ€™s disease
- Parkinsons Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245714
'Nasal administration of foralumab is an innovative immunotherapy which has potential for treatment of neurodegenerative diseases such ALS and progressive MS'.
IPSCIO Record ID: 223107
The term Patent Rights shall mean United States Patent Application Serial No. TBA, entitled 'Biomarkers for Neurodegenerative Disease,' filed TBA, which was developed by the Inventors, the inventions described and claimed therein, and all other pending United States patent applications or parts thereof and any United States patent which issues from any such pending applications and any and all divisions, reissues, re-examinations, renewals, continuations, continuations-in-part to the extent the claims are directed to subject matter specifically described in the aforementioned patent application and are dominated by the claims of the existing Patent Rights, and extensions thereof, and all other counterpart, pending or issued patents in all other countries.
Re: College OTA # 04-107 Entitled 'Serum Proteomic Methods and Biomarkers for Diagnosis of Neurodegenerative Disease and Differential Diagnosis of Alzheimers, Parkinsons Lou Gehrigs (ALS) Diseases, and other Motor Neuron and Neurological Disorders'
The term Licensed Product(s) shall mean any product, process or service that incorporates, utilizes or is made with the use of the Patent Rights.
IPSCIO Record ID: 26724
Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patientâ€™s nerve tissue.
IPSCIO Record ID: 28716
Licensor and Licensee are each pursuing various aspects of research in the field of Apheresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of the Pathophysiologic Basis of Diseases such as Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes.